Noriyuki Nagano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noriyuki Nagano has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Yukiko Nagano
Department of Health and Medical Science, Shinshu University Graduate School of Medicine, Matsumoto, Japan
31 shared publicationsShota Koide
Department of Medical Sciences, Shinshu University Graduate School of Medicine, Science and Technology, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
16 shared publicationsYoshichika Arakawa
Nagoya University Graduate School of Medicine, Nagoya, Japan
15 shared publications- Wataru Hayashi
Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan
14 shared publications Tomohiro Denda
Department of Health and Medical Science, Shinshu University Graduate School of Medicine, Matsumoto, Japan
12 shared publicationsYui Taniguchi
Department of Health and Medical Sciences, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
10 shared publications
Latest Publications
- 17 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103036
Occurrence of blaOXA-72 in a clinical isolate of carbapenem-resistant Acinetobacter pittii ST206 in Japan
- 17 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (9) , 103036
Occurrence of blaOXA-72 in a clinical isolate of carbapenem-resistant Acinetobacter pittii ST206 in Japan
- 5 May 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (8) , 2531-2539
Occurrence of healthcare-associated infections caused by the zoonotic bacterium Pasteurella multocida subsp. gallicida in patients with severe motor and intellectual disabilities in Japan
Pasteurella multocida is an important zoonotic pathogen that can cause human infections, exhibiting a wide clinical spectrum ranging from localised bite-wound infections to invasive infections, particularly in immunocompromised patients. The detection of P. multocida isolates from three patients with severe motor and intellectual disabilities (SMID) led to an investigation into the genomic relationship to explore nosocomial transmission. Three P. multocida strains were isolated from transtracheal aspirate cultures taken from three different inpatients in the SMID ward between January and February 2025. All strains were identified by phenotypic tests and MALDI-TOF MS. Whole-genome sequencing was performed to identify subspecies, analyze virulence genes, and explore phylogenetic relatedness. Three strains were identified as P. multocida subsp. gallicida, based on dDDH values of 89.6% and ANIm values of ≥98.89%. They belonged to novel sequence types multihost ST371 and RIRDC ST585, the capsular genotype of closest to type A, predominantly found in human respiratory pathogens, and the lipopolysaccharide genotypes of L1. They shared virulence genes encoding outer membrane proteins, adhesion factors, superoxide dismutases and hyaluronidases. The number of SNP differences between the three strains was found to be one or less, indicating that these strains are almost genetically indistinguishable. A noteworthy aspect of the present study is that it is the first to report intra-hospital transmission of P. multocida subsp. gallicida, as demonstrated through genome-level analysis. It is crucial to recognise that healthcare-associated infection caused by P. multocida can occur in specialised medical settings, such as wards for patients with SMID.
- 5 May 2026
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (8) , 2531-2539
Occurrence of healthcare-associated infections caused by the zoonotic bacterium Pasteurella multocida subsp. gallicida in patients with severe motor and intellectual disabilities in Japan
Pasteurella multocida is an important zoonotic pathogen that can cause human infections, exhibiting a wide clinical spectrum ranging from localised bite-wound infections to invasive infections, particularly in immunocompromised patients. The detection of P. multocida isolates from three patients with severe motor and intellectual disabilities (SMID) led to an investigation into the genomic relationship to explore nosocomial transmission. Three P. multocida strains were isolated from transtracheal aspirate cultures taken from three different inpatients in the SMID ward between January and February 2025. All strains were identified by phenotypic tests and MALDI-TOF MS. Whole-genome sequencing was performed to identify subspecies, analyze virulence genes, and explore phylogenetic relatedness. Three strains were identified as P. multocida subsp. gallicida, based on dDDH values of 89.6% and ANIm values of ≥98.89%. They belonged to novel sequence types multihost ST371 and RIRDC ST585, the capsular genotype of closest to type A, predominantly found in human respiratory pathogens, and the lipopolysaccharide genotypes of L1. They shared virulence genes encoding outer membrane proteins, adhesion factors, superoxide dismutases and hyaluronidases. The number of SNP differences between the three strains was found to be one or less, indicating that these strains are almost genetically indistinguishable. A noteworthy aspect of the present study is that it is the first to report intra-hospital transmission of P. multocida subsp. gallicida, as demonstrated through genome-level analysis. It is crucial to recognise that healthcare-associated infection caused by P. multocida can occur in specialised medical settings, such as wards for patients with SMID.
- Open Access
- 7 January 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (1)
Genetic and clinical landscape of methicillin-resistant Staphylococcus aureus isolates lacking the mec gene, in Japan
Objectives: The present study examines methicillin-resistant Staphylococcus aureus isolates lacking mec (MRLM) phenotypic and genotypic traits and clinical features of patients. Methods: Between October 2021 and February 2023, 13 MRLM isolates were identified among 867 S. aureus clinical isolates and subjected to WGS. Results: Ten of the 13 MRLMs were resistant to cefoxitin (MICs >4 mg/L), including two that were also resistant to oxacillin. The remaining three isolates were susceptible to both cefoxitin and oxacillin and exhibited typical growth on CHROMagar MRSA. Seven of the 13 isolates harboured the blaZ gene, but the hyperproduction of the β-lactamase encoded by this gene was not predicted. All isolates exhibited low MICs for cefazolin, ceftriaxone, imipenem, and meropenem and demonstrated susceptibility to the fifth-generation cephalosporin ceftobiprole. Ten STs/CCs, encompassing ST5, ST8, ST20, ST25, ST30, ST45 (3 isolates), ST291, ST398 (2 isolates), CC15 and CC22, identified among isolates, were within the range of previously reported MRLM clones. A multitude of previously reported or undocumented mutations/substitutions in PBPs, the pbp4 promoter, GdpP, YjbH and AcrB were identified. Four isolates had truncations or insertions in GdpP. The exploration of clinical features suggests the potential coexistence of MRLM and MSSA populations within each patient in the absence of antimicrobial selective pressure. Conclusions: The importance of accurate differentiation of MRLMs from MRSAs and MSSAs in routine laboratory testing is underscored by our results, which may allow in-depth investigation of the true epidemiology and clinical implications of MRLMs and the actual efficacy of β-lactams against them.
- 7 January 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (1)
Open AccessGenetic and clinical landscape of methicillin-resistant Staphylococcus aureus isolates lacking the mec gene, in Japan
Objectives: The present study examines methicillin-resistant Staphylococcus aureus isolates lacking mec (MRLM) phenotypic and genotypic traits and clinical features of patients. Methods: Between October 2021 and February 2023, 13 MRLM isolates were identified among 867 S. aureus clinical isolates and subjected to WGS. Results: Ten of the 13 MRLMs were resistant to cefoxitin (MICs >4 mg/L), including two that were also resistant to oxacillin. The remaining three isolates were susceptible to both cefoxitin and oxacillin and exhibited typical growth on CHROMagar MRSA. Seven of the 13 isolates harboured the blaZ gene, but the hyperproduction of the β-lactamase encoded by this gene was not predicted. All isolates exhibited low MICs for cefazolin, ceftriaxone, imipenem, and meropenem and demonstrated susceptibility to the fifth-generation cephalosporin ceftobiprole. Ten STs/CCs, encompassing ST5, ST8, ST20, ST25, ST30, ST45 (3 isolates), ST291, ST398 (2 isolates), CC15 and CC22, identified among isolates, were within the range of previously reported MRLM clones. A multitude of previously reported or undocumented mutations/substitutions in PBPs, the pbp4 promoter, GdpP, YjbH and AcrB were identified. Four isolates had truncations or insertions in GdpP. The exploration of clinical features suggests the potential coexistence of MRLM and MSSA populations within each patient in the absence of antimicrobial selective pressure. Conclusions: The importance of accurate differentiation of MRLMs from MRSAs and MSSAs in routine laboratory testing is underscored by our results, which may allow in-depth investigation of the true epidemiology and clinical implications of MRLMs and the actual efficacy of β-lactams against them.
- 20 October 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 955, 176901
Temporal dynamics of extended-spectrum β-lactamase-producing Escherichia coli and carbapenemase-producing Gram-negative bacteria in hospital wastewater
- 20 October 2024
- Published by Elsevier in Science of The Total Environment
- Vol. 955, 176901
Temporal dynamics of extended-spectrum β-lactamase-producing Escherichia coli and carbapenemase-producing Gram-negative bacteria in hospital wastewater
- Open Access
- 27 December 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 36, 139-141
Commonality of multispecies GES carbapenemase-producing organisms in hospital wastewater with those in previously investigated epidemiologically linked municipal wastewater influents
- 27 December 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 36, 139-141
Open AccessCommonality of multispecies GES carbapenemase-producing organisms in hospital wastewater with those in previously investigated epidemiologically linked municipal wastewater influents
- Open Access
- 19 December 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 36, 62-64
Comparative analysis of blaNDM-1-carrying plasmids harboured by four different Acinetobacter species from hospital environments and patients during 2018–2022
- 19 December 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 36, 62-64
Open AccessComparative analysis of blaNDM-1-carrying plasmids harboured by four different Acinetobacter species from hospital environments and patients during 2018–2022
- Open Access
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0218823
Municipal wastewater monitoring revealed the predominance of bla GES genes with diverse variants among carbapenemase-producing organisms: high occurrence and persistence of Aeromonas caviae harboring the new bla GES variant bla GES-48
We characterized carbapenemase-producing organism (CPO) detected in municipal wastewater to better understand the epidemiology of CPOs in the community. In total, 36 samples were collected at six sampling sites every other month from December 2020 to October 2021. CPOs were not recovered from influent taken from inlet A receiving separated sewer line, treated effluents, and river water samples upstream and downstream of the effluent outlet. By contrast, 75 CPOs were detected in all influent samples taken from inlets B and C receiving combined sewer lines collecting both domestic/industrial wastewater and rainwater runoff. Aeromonas caviae was the dominant species (25/75, 33.3%), and the other 11 Aeromonas spp. together accounted for 48% of CPOs. The remaining 39 Enterobacterales strains mainly comprised 17 Klebsiella spp. and 10 Raoultella spp. CPOs carrying bla GES carbapenemase genes were overwhelmingly dominant, accounting for 72 of 75 isolates, including two isolates harboring both bla GES-24 and bla IMP-1 (96%), followed by three bla IMPs -positive isolates, where those carbapenemase genes were mainly carried in diverse class 1 integrons. Among bla GES variants, including six new variants ( bla GES-47 , bla GES-48 , bla GES-49 , bla GES-50 , bla GES-51 , and bla GES-54 ), bla GES-5 was detected in 28 CPOs, with Aeromonas spp. accounting for 53.6% of these organisms. Quantitative analysis revealed that the repeated detection of bla GES-48 -positive A. caviae ST1056 from both inlets B and C ranked the total number of this bacterial clone highest in the wastewater influent. In summary, our study revealed the high prevalence and persistence of diverse bla GES carbapenemase genes among CPOs isolated from influent inlets connected to combined sewer systems. IMPORTANCE: The emergence and spread of carbapenemase-producing organisms (CPOs) represent a global health threat because they are associated with limited treatment options and poor clinical outcomes. Wastewater is considered a hotspot for the evolution and dissemination of antimicrobial resistance. Thus, analyses of municipal wastewater are critical for understanding the circulation of these CPOs and carbapenemase genes in local communities, which remains scarcely known in Japan. This study resulted in several key observations: (i) the vast majority of bla GES genes, including six new bla GES variants, and less frequent bla IMP genes were carbapenemase genes encountered exclusively in wastewater influent; (ii) the most dominant CPO species were Aeromonas spp., in which a remarkable diversity of new sequence types was observed; and (iii) CPOs were detected from combined sewer wastewater, but not from separate sewer wastewater, suggesting that the load of CPOs from unrecognized environmental sources could greatly contribute to their detection in influent wastewater.
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0218823
Open AccessMunicipal wastewater monitoring revealed the predominance of bla GES genes with diverse variants among carbapenemase-producing organisms: high occurrence and persistence of Aeromonas caviae harboring the new bla GES variant bla GES-48
We characterized carbapenemase-producing organism (CPO) detected in municipal wastewater to better understand the epidemiology of CPOs in the community. In total, 36 samples were collected at six sampling sites every other month from December 2020 to October 2021. CPOs were not recovered from influent taken from inlet A receiving separated sewer line, treated effluents, and river water samples upstream and downstream of the effluent outlet. By contrast, 75 CPOs were detected in all influent samples taken from inlets B and C receiving combined sewer lines collecting both domestic/industrial wastewater and rainwater runoff. Aeromonas caviae was the dominant species (25/75, 33.3%), and the other 11 Aeromonas spp. together accounted for 48% of CPOs. The remaining 39 Enterobacterales strains mainly comprised 17 Klebsiella spp. and 10 Raoultella spp. CPOs carrying bla GES carbapenemase genes were overwhelmingly dominant, accounting for 72 of 75 isolates, including two isolates harboring both bla GES-24 and bla IMP-1 (96%), followed by three bla IMPs -positive isolates, where those carbapenemase genes were mainly carried in diverse class 1 integrons. Among bla GES variants, including six new variants ( bla GES-47 , bla GES-48 , bla GES-49 , bla GES-50 , bla GES-51 , and bla GES-54 ), bla GES-5 was detected in 28 CPOs, with Aeromonas spp. accounting for 53.6% of these organisms. Quantitative analysis revealed that the repeated detection of bla GES-48 -positive A. caviae ST1056 from both inlets B and C ranked the total number of this bacterial clone highest in the wastewater influent. In summary, our study revealed the high prevalence and persistence of diverse bla GES carbapenemase genes among CPOs isolated from influent inlets connected to combined sewer systems. IMPORTANCE: The emergence and spread of carbapenemase-producing organisms (CPOs) represent a global health threat because they are associated with limited treatment options and poor clinical outcomes. Wastewater is considered a hotspot for the evolution and dissemination of antimicrobial resistance. Thus, analyses of municipal wastewater are critical for understanding the circulation of these CPOs and carbapenemase genes in local communities, which remains scarcely known in Japan. This study resulted in several key observations: (i) the vast majority of bla GES genes, including six new bla GES variants, and less frequent bla IMP genes were carbapenemase genes encountered exclusively in wastewater influent; (ii) the most dominant CPO species were Aeromonas spp., in which a remarkable diversity of new sequence types was observed; and (iii) CPOs were detected from combined sewer wastewater, but not from separate sewer wastewater, suggesting that the load of CPOs from unrecognized environmental sources could greatly contribute to their detection in influent wastewater.
- Open Access
- 2 November 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 35, 322-324
A novel blaNDM-1-carrying multidrug-resistant genomic island GIMmSU8481 in a faecal Morganella morganii subsp. sibonii isolate from a patient
- 2 November 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 35, 322-324
Open AccessA novel blaNDM-1-carrying multidrug-resistant genomic island GIMmSU8481 in a faecal Morganella morganii subsp. sibonii isolate from a patient
- Open Access
- 31 July 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 34, 211-213
Novel genomic island carrying a new vanD allele in a vancomycin-resistant Enterococcus faecium clinical isolate belonging to clade A1 in Japan
- 31 July 2023
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 34, 211-213
Open AccessNovel genomic island carrying a new vanD allele in a vancomycin-resistant Enterococcus faecium clinical isolate belonging to clade A1 in Japan